AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7932276 — intervention group
Group type: COMPARATOR
Intervention: No-light control (quiet activities at 0600 hours)
Number of subjects: 24
Study 2974463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium/fenoterol (250 micrograms/625 micrograms)
Number of subjects: 47
Study 2974463 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (625 micrograms)
Number of subjects: 47
Study 2974463 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (250 micrograms)
Number of subjects: 47
Study 2974463 — intervention group
Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 47
Study 30121596 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (GPs) including training in dementia screening and management guidelines.
Number of subjects: 2030
Study 30121596 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (GPs)
Number of subjects: 2030
Study 27516541 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein plus potassium bicarbonate (WP+KHCO3)
Number of subjects: 10
Study 27516541 — intervention group
Group type: COMPARATOR
Intervention: Standardized isocaloric diet (Control)
Number of subjects: 10
Study 26543236 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) based on three SNPs (rs9349407, rs11218343, rs17125944)
Number of subjects: 1210
Study 26543236 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE
Number of subjects: 1210
Study 26543236 — intervention group
Group type: EXPERIMENTAL
Intervention: GRS and APOE combined
Number of subjects: 1210
Study 26543236 — intervention group
Group type: COMPARATOR
Intervention: Discovery set SNPs
Number of subjects: 1210
Study 22985056 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary limit pop-up reminder
Number of subjects: 59
Study 22985056 — intervention group
Group type: COMPARATOR
Intervention: No monetary limit pop-up reminder
Number of subjects: 59
Study 20705785 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI-directed fluid management
Number of subjects: 82
Study 20705785 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 82
Study 19119578 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF mouth rinse (G1)
Number of subjects: 170
Study 19119578 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF + 0.12% CHX mouth rinse (G2)
Number of subjects: 170
Study 15784928 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 58
Study 15784928 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular ketorolac (30 mg)
Number of subjects: 58
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 350
Study 12393590 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin and cytarabine (DA)
Number of subjects: 350
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: DA and ATRA
Number of subjects: 350
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and observation
Number of subjects: 350
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA and ATRA
Number of subjects: 350
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA
Number of subjects: 350
Study 12393590 — intervention group
Group type: COMPARATOR
Intervention: DA
Number of subjects: 350
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 350
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical M3 morphology
Number of subjects: 350
Study 12393590 — intervention group
Group type: EXPERIMENTAL
Intervention: Age more than 15 years
Number of subjects: 350
Study 10344626 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate 200 microg day(-1)
Number of subjects: 43
Study 10344626 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate 400 microg day(-1)
Number of subjects: 43
Study 10344626 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate 800 microg day(-1)
Number of subjects: 43
Study 10344626 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-beclomethasone dipropionate 800 microg day(-1)
Number of subjects: 43
Study 10344626 — intervention group
Group type: COMPARATOR
Intervention: HFA-placebo
Number of subjects: 43
Study 7491331 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 18
Study 7491331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no theophylline treatment)
Number of subjects: 18
Study 1773467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine (120‐160mg/d)
Number of subjects: 75
Study 1773467 — intervention group
Group type: COMPARATOR
Intervention: Control group (magnesium sulfate 20‐25g/d)
Number of subjects: 75
Study 6114776 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of benzodiazepines (placebo-controlled, double-blind)
Number of subjects: 16
Study 6114776 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal of benzodiazepines
Number of subjects: 16
Study 31978689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure therapy
Number of subjects: 0
Study 31978689 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 31791637 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥45 kg/m2
Number of subjects: 150
Study 31791637 — intervention group
Group type: COMPARATOR
Intervention: BMI 35.0‐44.9 kg/m2
Number of subjects: 150
Study 31791637 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 150
Study 27704544 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week mindfulness training
Number of subjects: 50
Study 27704544 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 27282690 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment using a short leg cast or splint (Group A)
Number of subjects: 29
Study 27282690 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) (Group B)
Number of subjects: 29
Study 27282690 — intervention group
Group type: COMPARATOR
Intervention: Short leg cast only (Group C)
Number of subjects: 29
Study 25141360 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (3 times per week classes and at least 2 times per week at home)
Number of subjects: 40
Study 25141360 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 25141360 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention
Number of subjects: 40
Study 23373678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuld Object-Memory Evaluation (FOME) alternate form
Number of subjects: 102
Study 19910177 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 10mg at bedtime
Number of subjects: 14
Study 19910177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18224400 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (2.5 Gy or more)
Number of subjects: 0
Study 18224400 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study 16818146 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 172
Study 16818146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 14624026 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosage of vitamin C
Number of subjects: 20
Study 14624026 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dosage of vitamin E
Number of subjects: 20
Study 14624026 — intervention group
Group type: COMPARATOR
Intervention: CSF: plasma ratio of vitamin C
Number of subjects: 20
Study 14624026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal volume in AD patients
Number of subjects: 20
Study 10900277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg orally twice daily) and 0.45 percent saline intravenously
Number of subjects: 83
Study 10900277 — intervention group
Group type: COMPARATOR
Intervention: Placebo and saline
Number of subjects: 83
Study 8922661 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 151
Study 8922661 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 151
Study 8922661 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential HRT
Number of subjects: 151
Study 8922661 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT treatment groups
Number of subjects: 151
Study 8922661 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 151
Study 8922661 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 151
Study 1447502 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meal
Number of subjects: 68
Study 1447502 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 68
Study 4064528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (Hexabrix)
Number of subjects: 0
Study 4064528 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol (Niopam)
Number of subjects: 0
Study 4064528 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (Omnipaque)
Number of subjects: 0
Study 30847930 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen administration (EE)
Number of subjects: 27
Study 30847930 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin B receptor (ETB R) inhibition (BQ-788)
Number of subjects: 27
Study 30847930 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution alone
Number of subjects: 27
Study 30847930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone
Number of subjects: 27
Study 30021634 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 1-3 months before IVF-ET
Number of subjects: 0
Study 30021634 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 1-3 months before IVF-ET
Number of subjects: 0
Study 26881317 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 304
Study 26881317 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 304
Study 26881317 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 304
Study 26881317 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study 1582098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 21
Study 1582098 — intervention group
Group type: COMPARATOR
Intervention: Reintroduction of provoking foods
Number of subjects: 21
Study 1582098 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled reintroduction of provoking foods
Number of subjects: 21
Study 22318199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea/phlebotomy
Number of subjects: 133
Study 22318199 — intervention group
Group type: COMPARATOR
Intervention: Transfusions/chelation
Number of subjects: 133
Study 19793218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic aerobic high-intensity interval training (24 sessions, 4x4 min in hyperoxia at 85-95% peak heart rate)
Number of subjects: 6
Study 19793218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic aerobic high-intensity interval training
Number of subjects: 6
Study 19793218 — intervention group
Group type: COMPARATOR
Intervention: Acute hyperoxia
Number of subjects: 6
Study 18775878 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (discharged 24h after first PM implant or 4-6h after replacement, followed with Home-Monitoring for 4 weeks)
Number of subjects: 379
Study 18775878 — intervention group
Group type: COMPARATOR
Intervention: Control group (followed for 4 weeks according to usual medical practices)
Number of subjects: 379
Study 18775878 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 379
Study 16327752 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based breast cancer screening interventions
Number of subjects: 156
Study 16327752 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based cervical cancer screening interventions
Number of subjects: 156
Study 16327752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cervical and breast cancer screening interventions
Number of subjects: 156
Study 16327752 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based colorectal cancer screening interventions
Number of subjects: 156
Study 12975409 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha blocker
Number of subjects: 22
Study 12975409 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker
Number of subjects: 22
Study 12975409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alpha and beta blockade
Number of subjects: 22
Study 12975409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12975409 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study 10656234 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of thioctic acid (TA) t.i.d. for 3 weeks
Number of subjects: 24
Study 10656234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9032849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife surgery
Number of subjects: 16
Study 1523284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (12.5 mg orally)
Number of subjects: 72
Study 1523284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (25 mg orally)
Number of subjects: 72
Study 1523284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2.5 mg orally)
Number of subjects: 72
Study 1523284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 4043516 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 9
Study 4043516 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide-triamterene combination
Number of subjects: 9
Study 31142081 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual 5 mg nifedipine dripping pills
Number of subjects: 482
Study 31142081 — intervention group
Group type: COMPARATOR
Intervention: Sublingual 10 mg nifedipine dripping pills
Number of subjects: 482
Study 29034961 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated intermittent boluses with 16 mg ropivacaine every 2 hours combined with patient-controlled administration
Number of subjects: 70
Study 29034961 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of 8 mg/h (4 ml/h) of ropivacaine combined with patient-controlled administration (2 ml, lockout time 30 min)
Number of subjects: 70
Study 27061887 — intervention group
Group type: COMPARATOR
Intervention: Full dose subcutaneous zoster vaccine
Number of subjects: 224
Study 27061887 — intervention group
Group type: COMPARATOR
Intervention: 1/3 dose subcutaneous zoster vaccine
Number of subjects: 224
Study 27061887 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose intradermal zoster vaccine
Number of subjects: 224
Study 27061887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/3 dose intradermal zoster vaccine
Number of subjects: 224
Study 27061887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10 dose intradermal zoster vaccine
Number of subjects: 224
Study 27061887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/27 dose intradermal zoster vaccine
Number of subjects: 224
Study 27061887 — intervention group
Group type: EXPERIMENTAL
Intervention: All intradermal doses
Number of subjects: 224
Study 27061887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 224
Study 24659236 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide (100 mg tid) + LDA (100 mg once-daily)
Number of subjects: 32
Study 24659236 — intervention group
Group type: COMPARATOR
Intervention: placebo (tid) + LDA
Number of subjects: 32
Study 24659236 — intervention group
Group type: COMPARATOR
Intervention: placebo + LDA + clopidogrel (75 mg once-daily)
Number of subjects: 32
Study 24659236 — intervention group
Group type: EXPERIMENTAL
Intervention: rebamipide + LDA + clopidogrel
Number of subjects: 32
Study 20435668 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty
Number of subjects: 0
Study 16415603 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 1.0 mg
Number of subjects: 63
Study 16415603 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 0.5 mg
Number of subjects: 63
Study 16415603 — intervention group
Group type: COMPARATOR
Intervention: Saline 1 ml
Number of subjects: 63
Study 12570169 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (7.5 mg continuously) combined with clomiphene citrate (150 mg from day 5 to 9)
Number of subjects: 100
Study 12570169 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with clomiphene citrate (150 mg from day 5 to 9)
Number of subjects: 100
Study 12570169 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine treatment
Number of subjects: 100
Study 12570169 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine and placebo treatment
Number of subjects: 100
Study 9456562 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: 38 children (76 eyes) with birth weight from 580 to 1500 g (mean 1158 g)
Number of subjects: 90
Study 9456562 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II: 52 children (104 eyes) with birth weight from 1501 to 2450 g (mean 2093 g)
Number of subjects: 90
Study 8147516 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 100
Study 8147516 — intervention group
Group type: COMPARATOR
Intervention: 26-gauge needle
Number of subjects: 100
Study 2844546 — intervention group
Group type: EXPERIMENTAL
Intervention: RX77368 infusion
Number of subjects: 6
Study 2844546 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone during RX77368 infusion
Number of subjects: 6
Study 11445770 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric overload (EO) training, N = 10
Number of subjects: 30
Study 11445770 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard training (ST), N = 10
Number of subjects: 30
Study 11445770 — intervention group
Group type: COMPARATOR
Intervention: Control group (C), N = 10
Number of subjects: 30
Study 31276454 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose 1 (0.06%)
Number of subjects: 39
Study 31276454 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose 2 (0.08%)
Number of subjects: 39
Study 31276454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30127189 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instructions
Number of subjects: 33
Study 30127189 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic instructions
Number of subjects: 33
Study 30127189 — intervention group
Group type: COMPARATOR
Intervention: Visual instructions without video and charts (Group 1)
Number of subjects: 33
Study 27007062 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200-3000 mg/d)
Number of subjects: 66
Study 27007062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 24275208 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored information pack
Number of subjects: 76
Study 24275208 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard information)
Number of subjects: 76
Study 24275208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 22333993 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin (TC)
Number of subjects: 41
Study 20598975 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 266
Study 20598975 — intervention group
Group type: COMPARATOR
Intervention: Late invasive strategy
Number of subjects: 266
Study 17630391 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoCapture-controlled pacing
Number of subjects: 62
Study 17630391 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacing
Number of subjects: 62
Study 15847313 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% rimexolone
Number of subjects: 78
Study 15847313 — intervention group
Group type: COMPARATOR
Intervention: 1% prednisolone acetate
Number of subjects: 78
Study 11669432 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil anaesthesia (boluses and infusion)
Number of subjects: 20
Study 9855217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical photostimulation with filtered visible light for 12, 14, and 16 minutes for a period of 6 weeks
Number of subjects: 7
Study 7986390 — intervention group
Group type: COMPARATOR
Intervention: TNF beta * 1 allele in TBII positive atrophic autoimmune thyroiditis patients
Number of subjects: 48
Study 7986390 — intervention group
Group type: COMPARATOR
Intervention: HLA-DR8 positive patients with TBII-positive atrophic autoimmune thyroiditis
Number of subjects: 48
Study 2590268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone (n = 5)
Number of subjects: 14
Study 2590268 — intervention group
Group type: EXPERIMENTAL
Intervention: Latamoxef (n = 5)
Number of subjects: 14
Study 2590268 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (control, n = 4)
Number of subjects: 14
Study 4603037 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine-pyrimethamine
Number of subjects: 0
Study 4603037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfalene-pyrimethamine
Number of subjects: 0
Study 30362981 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive and resistive electric transfer (CRET) therapy
Number of subjects: 53
Study 30362981 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 53
Study 28249576 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person, group-based intervention (13 sessions; n=215)
Number of subjects: 651
Study 28249576 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (13 modules; n=225)
Number of subjects: 651
Study 28249576 — intervention group
Group type: COMPARATOR
Intervention: Control group (printed educational materials; n=211)
Number of subjects: 651
Study 25924668 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized Option B+ approach (immediate ART initiation upon diagnosis)
Number of subjects: 94000